#### Medicare Advantage and Dual Eligible Special Needs Plans prior authorization and notification list

Effective date: 1/1/2026

**Revision date:** 

(Select to navigate to Prior Authorization List [PAL])

We have updated our prior authorization and notification list for Humana Medicare Advantage and Dual Eligible Special Needs (D-SNP) plans.

Please note the term "prior authorization" (preauthorization, precertification), when used in this communication, is defined as a process through which the physician or other healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.

The list details medications (i.e., medications that are delivered in the physician's office, clinic, outpatient or home setting) that require prior authorization before being provided or administered. Services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS). According to the guidelines, all medical care, services, supplies and equipment must be medically necessary. You can review Medicare coverage guidelines on the CMS website.

To view Humana's Medical and Pharmacy Coverage Policies, please visit <u>Humana's Medical and Pharmacy Coverage</u> Policies website.

Investigational and experimental procedures and devices usually are not covered benefits. Please consult the patient's Evidence of Coverage or contact Humana for confirmation of coverage.

Please note that certain services may not be covered under the member's plan.

#### Important notes:

Humana Medicare Advantage (MA) health maintenance organization (HMO): The full list of prior authorization requirements applies to patients with Humana MA HMO and HMO point-of-service (HMO POS) coverage. Healthcare providers who participate in an independent practice association (IPA) or other risk network with delegated services are subject to the PAL and should refer to their IPA or risk network for guidance on processing their requests. Exclusions may change, so please refer to <a href="https://example.com/humana/sproviderwebsite"><u>Humana/sproviderwebsite</u></a> for the most up-to-date information.

**Florida MA HMO**: The full list of prior authorization requirements applies to Florida MA HMO-covered patients. Healthcare providers should submit requests directly to Humana for medications listed on the MA and D-SNP medication PAL for all patients with Humana MA HMO coverage in Florida. If Humana does not receive a prior authorization request, the claim may be reviewed retrospectively for medical necessity, and the healthcare provider may be contacted for clinical information. See "How to Request"

# Humana,

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Prior authorization" for instructions on how to submit prior authorization requests for medications on the MA and D-SNP Medication PAL.

**Humana MA private fee-for-service (PFFS)**: Prior authorization is not required for MA PFFS plans. However, notification is requested because it helps coordinate care for Humana-covered patients. Physicians and healthcare providers can request an advance coverage determination (ACD) for review and determination of coverage in advance of the services being provided (on behalf of the patient for any service not on our PAL). See "Advance Coverage Determinations" for instructions.

**Humana MA preferred provider organization (PPO)**: The full list of prior authorization requirements applies to patients with Humana MA PPO coverage.

**Humana Medicare Supplement Insurance Plan**: This list does not apply to policyholders of a Humana Medicare Supplement Insurance Plan.

**All Humana MA plans**: For procedures or services that are investigational or experimental (or that may have limited benefit coverage), or to learn if Humana will pay for a service, you can request an ACD on behalf of the patient prior to providing the service. You may be contacted if additional information is needed.

ACDs for medications on the list can be initiated by submitting a fax or phone request: Submit by phone at 866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m., Eastern time, or by fax to 888-447-3430.

To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment. Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment. To ensure appropriate claim payment, please include the modifier based on Humana's Medicare Advantage Payment Policy (CP2023011), which can be found on <a href="Humana's claims payment policies">Humana's claims payment policies</a> website, or include medical records with evidence that the member is in an active course of treatment.

#### Additional information related to step therapy for Medicare Part B medications:

Humana's Medicare Part B Step Therapy Preferred Drug List (PDL), which includes background information about the program and a comprehensive list of preferred and nonpreferred medications, is available at <a href="https://example.com/humana's provider prior authorization notification lists website">https://example.com/humana's provider prior authorization notification lists website</a>.

Some step therapy strategies for Medicare Advantage prescription drug plans may require a trial of a preferred medication across different benefits, such as Medicare Part B and Part D. Details regarding these cross-benefit strategies can be found on Humana's Part B Step Therapy PDL, which is available on <a href="Humana's provider prior authorization notification lists website">Humana's provider prior authorization notification lists website</a>.

Humana's Part B Step Therapy PDL should be reviewed in conjunction with Humana's coverage policies, which are accessible on Humana's Medical and Pharmacy Coverage Policies website.

The designation of preferred status does not guarantee exemption from step therapy requirements. Please refer

# Humana。

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

to the specific criteria contained in our coverage criteria policies, which is available on Humana's <u>Medical and Pharmacy Coverage Policies website</u>. Affected medications are noted with a step therapy indicator on the Medicare PAL at Humana's provider prior authorization notification lists website.

If providers do not stock a preferred medication, they may be able to obtain the preferred medication from a pharmacy (e.g., a pharmacy can ship the medication to the office). Please review our list of specialty and mail-order pharmacies at <a href="https://documents.com/humana/s-mail-order-webpage">https://documents.com/humana/s-mail-order-webpage</a> to select a pharmacy that can provide the medication. A full list of pharmacies also is available on the <a href="https://documents.com/humana/s-mail-order-webpage">pharmacy finder tool</a>.

If you have questions, please call us at 800-457-4708 (TTY: 711), daily, 8 a.m. – 8 p.m., Eastern time. However, please note that our automated phone system may answer your call during weekends and holidays from April 1 to Sept. 30. Please leave your name and phone number and we'll call you back by the end of the next business day. For 24-hour service, please visit <a href="https://example.com/humana/swebsite">https://example.com/humana/swebsite</a>.

#### Please note that urgent/emergent services do not require referrals or prior authorizations.

Not obtaining prior authorization for a service could result in financial penalties for the practice and reduced benefits for the patient based on the healthcare provider's contract and the patient's Evidence of Coverage. Services or medications provided without prior authorization may be subject to retrospective medical necessity review. We recommend that an individual practitioner making a specific request for services or medications verify benefits and prior authorization requirements with Humana prior to providing services.

# Information required for a prior authorization request or notification may include, but is not limited to, the following:

- Patient name, date of birth and Humana member ID number
- Date of actual service or hospital admission
- Healthcare Common Procedure Coding System (HCPCS) code(s) and diagnosis codes (primary and secondary) (up to a maximum of 6 per authorization request)
- Service location
  - o Inpatient (acute hospital, skilled nursing or hospice)
  - Outpatient (telehealth, office, home, off-campus outpatient hospital, on-campus outpatient hospital or ambulatory surgery center)
- Tax Identification Number (TIN), National Provider Identifier (NPI) of facility where service is being rendered, and TIN and NPI number of the provider performing the service
- Caller/requester's name and phone number and attending physician's phone number
- Relevant clinical information

Submitting all relevant clinical information at the time of the request will help expedite determination. If additional clinical information is required, a Humana representative will request the specific information needed to complete the authorization process.

#### How to request prior authorization:

Except where noted in the list below, prior authorization for medications may be initiated in one of 3 ways:

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

- Online: CoverMyMeds
- Phone number: 866-461-7273 (TTY: 711), Monday Friday, 8 a.m. 11 p.m., Eastern time
- Fax number: 888-447-3430 (request forms available on Humana's <u>prior authorization for</u> professionally administered drugs website)

The list below is subject to change with notification and may be modified throughout the year for additions of new-to-market medications or step therapy requirements for medications without notification by United States Postal Service mail.

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Access the fax forms to request preauthorization or provide notification.		
Brand medication name	Generic medication name	Billing codes
Abecma intravenous suspension <sup>††</sup>	idecabtagene vicleucel <sup>††</sup>	Q2055
Abraxane <sup>‡,**</sup>	nab-paclitaxel <sup>‡,**</sup>	J9264
Actemra IV**	tocilizumab**	J3262
Adakveo	crizanlizumab-tmca	J0791
Adcetris	brentuximab vedotin	J9042
Adstiladrin	nadofaragene firadenovec-vncg	J9029
Aduhelm	aducanumab-avwa	J0172
Adzynma	ADAMTS13, recombinant-krhn	J7171
Akynzeo IV	fosnetupitant and palonosetron	J1454
Aldurazyme	laronidase	J1931
Alimta <sup>‡</sup>	pemetrexed <sup>‡</sup>	J9305
Alyglo	immune globulin intravenous, human-stwk**	J1552
Alymsys**	bevacizumab-maly <sup>**</sup>	Q5126
Amondys-45	casimersen	J1426
Amtagvi	lifileucel <sup>‡,††</sup>	C9399, J3490, J9999
Amvuttra	vutrisiran	J0225
Anktiva	nogapendekin alfa inbakicept-pmln	J9028
Aphexda	motixafortide	J2277
Aralast NP <sup>‡, **</sup>	alpha 1-proteinase inhibitor <sup>‡, **</sup>	J0256
Aranesp**	darbepoetin alfa**	J0881
Asceniv**	immune globulin**	J1554
Asparlas	calaspargase pegol-mknl	J9118

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Aucatzyl <sup>††</sup>	obecabtagene autoleucel <sup>††</sup>	Q2058
Avastin <u>(authorization required only</u> <u>for oncology/chemo use)</u> **	bevacizumab (oncology only) **	C9257, J9035
Aveed	testosterone undecanoate	J3145
Avsola <sup>‡,**</sup>	infliximab-axxq <sup>‡,**</sup>	Q5121
Avtozma IV *,**	tocilizumab-anoh *,**	Q5156
Axtle <sup>‡</sup>	pemetrexed <sup>‡</sup>	J9292
Azedra	iobenguane I 131	A9590
Bavencio	avelumab	J9023
Beizray <sup>*,†</sup>	docetaxel-albumin *,†	J9174
Beleodaq	belinostat	J9032
Belrapzo <sup>‡</sup>	bendamustine hydrochloride <sup>‡</sup>	J9036
bendamustine <sup>‡</sup>	bendamustine hydrochloride <sup>‡</sup>	J9036
bendamustine (Apotex)	bendamustine hydrochloride	J9058
bendamustine (Baxter)	bendamustine hydrochloride	J9059
Bendeka	bendamustine hydrochloride	J9034
Benlysta	belimumab	C9399, J0490, J3590
Beovu**	brolucizumab-dbll <sup>**</sup>	J0179
Berinert**	c1 esterase inhibitor**	J0597
Besponsa	Inotuzumab ozogamicin	J9229
Bildyos *,t,#,**	denosumab-nxxp *,†,‡,**	C9399, J3490, J3590, J9999
Bilprevda *,t,‡,**	denosumab-nxxp <sup>*,†,‡,**</sup>	C9399, J3490, J3590, J9999
Bivigam <sup>**</sup>	immune globulin**	J1556
Bizengri	zenocutuzumab-zbco	J9382
Bkemv IV	eculizumab-aeeb **	Q5152

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Blenrep <sup>‡</sup>	belantamab mafodotin-blmf‡	J9037
Blincyto	blinatumomab	J9039
Bloc	od-clotting factors (see list on pages 25-	–27)
Bomyntra*,†,‡,**	denosumab-bnht <sup>*,†,‡,**</sup>	Q5158
bortezomib <sup>‡</sup>	bortezomib <sup>‡</sup>	J9041
bortezomib (Dr. Reddy's)	bortezomib	J9046
bortezomib (Fresenius Kabi)	bortezomib	J9048
bortezomib (Hospira)	bortezomib	J9049
bortezomib (Maia)	bortezomib	J9051
Boruzu	bortezomib	J9054
Botox	onabotulinumtoxinA	J0585
Brineura	cerliponase alfa	J0567
Briumvi	ublituximab-xiiy **	J2329
Breyanzi <sup>††</sup>	lisocabtagene maraleucel	Q2054
Byooviz **	ranibizumab-nuna intravitreal solution **	Q5124
Carvykti <sup>††</sup>	ciltacabtagene autoleucel <sup>††</sup>	Q2056
# Casgevy	exagamglogene autotemcel #	J3392
Cerezyme **	imiglucerase **	J1786
Cimzia **	certolizumab pegol **	J0717
Cinqair	reslizumab	J2786
Cinryze**	c1 esterase inhibitor (human)**	J0598
Conexxence*,†,**	denosumab-bnht <sup>*,†,‡,**</sup>	Q5158
Cosela	trilaciclib	J1448

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Columvi	glofitamab-gxbm tt	J9286
Cosentyx IV	secukinumab**	J3247
Crysvita	burosumab-twza	J0584
Cutaquig**	immune globulin**	J1551
Cuvitru**	immune globulin	J1555
Cyramza	ramucirumab	J9308
Danyelza	naxitamab-gqgk	J9348
Darzalex	daratumumab	J9145
Darzalex Faspro‡	daratumumab and hyaluronidase-fihj <sup>‡</sup>	J9144
Datroway	datopotamab-deruxtecan-dlnk	J9011
Dawnzera *,†,‡,**	donidalorsen *,†,‡,**	C9399, J3490
Daxxify	daxibotulinumtoxinA-lanm	J0589
Defitelio <sup>‡</sup>	defibrotide sodium <sup>‡</sup>	C9399, J3490
Docivyx	docetaxel	J9172
Doxil	doxorubicin HCL liposome injection	Q2050
Durysta <sup>‡</sup>	bimatoprost implant <sup>‡</sup>	J7351
Dysport	abobotulinumtoxin A	J0586
Elahere	mirvetuximab soravtansine-gynx	J9063
Elaprase	idursulfase	J1743
Elelyso	taliglucerase alfa	J3060

# Humana,

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- $\dagger\dagger$  Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Elevidys	delandistrogene moxeparvovec-rokl	J1413
Elfabrio IV	pegunigalsidase alfa-iwxj	J2508
Elrexfio	elranatamab-bcmm	J1323
Elzonris	tagraxofusp-erzs	J9269
Empaveli <sup>‡</sup>	pegcetacoplan <sup>‡</sup>	C9399, J3490
Empliciti	elotuzumab	J9176
Emrelis IV <sup>‡</sup>	telisotuzumab vedotin-tllv <sup>‡</sup>	C9306, J3490, J3590, J9999
Encelto	revakinagene taroretcel-lwey	J3403
Enhertu	fam-trastuzumab deruxtecan-nxki	J9358
Enjaymo	sutimlimab-jome	J1302
Enspryng <sup>‡</sup>	satralizumab-mwge <sup>‡</sup>	C9399, J3490, J3590
Entyvio IV**	vedolizumab <sup>**</sup>	J3380
Epkinly	epcoritamab-bysp	J9321
Epogen <sup>‡,**</sup>	epoetin alfa <sup>‡,**</sup>	J0885
Epysqli IV	eculizumab-aagh **	Q5151
Erbitux	cetuximab	J9055
Erwinase <sup>‡</sup>	crisantaspase <sup>‡</sup>	J9019
Euflexxa**	sodium hyaluronate **	J7323
Evenity**	romosozumab-aqqg**	J3111
Evkeeza **	evinacumab-dgnb **	J1305
Exondys 51	eteplirsen	J1428

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- $\dagger\dagger$  Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Eylea**	aflibercept <sup>**</sup>	J0178
Eylea HD **	aflibercept <sup>**</sup>	J0177
Fabrazyme	agalsidase beta	J0180
Fasenra	benralizumab	J0517
Faslodex	fulvestrant	J9395
Feraheme**	ferumoxytol**	Q0138
Firazyr <sup>‡,**</sup>	icatibant <sup>‡,**</sup>	J1744
Flebogamma DIF <sup>‡</sup>	immune globulin <sup>‡</sup>	J1572
Folotyn <sup>‡</sup>	pralatrexate <sup>‡</sup>	J9307
Fulphila	pegfilgrastim-jmdb	Q5108
fulvestrant (Teva)	fulvestrant	J9393
fulvestrant (Fresenius Kabi)	fulvestrant	J9394
Fusilev <sup>‡</sup>	levoleucovorin calcium <sup>‡</sup>	J0641
Fyarro	sirolimus protein-bound particles for injectable suspension	J9331
Fylnetra **	pegfilgrastim-pbbk	Q5130
GamaSTAN <sup>‡</sup>	immune globulin <sup>‡</sup>	J1460, J1560
GamaSTAN S/D‡	immune globulin <sup>‡</sup>	J1460, J1560
Gamifant	emapalumab-lzsg	J9210
Gammagard	immune globulin	J1569
Gammagard S/D <sup>‡</sup>	immune globulin <sup>‡</sup>	J1566

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Gammaked <sup>‡</sup>	immune globulin <sup>‡</sup>	J1561
Gammaplex**	immune globulin**	J1557
Gamunex-C <sup>‡</sup>	immune globulin <sup>‡</sup>	J1561
Gazyva	obinutuzumab	J9301
Gel-One**	sodium hyaluronate <sup>**</sup>	J7326
Gelsyn-3 <sup>**</sup>	sodium hyaluronate**	J7328
Genvisc 850**	sodium hyaluronate <sup>**</sup>	J7320
Givlaari	givosiran	J0223
Glassia**	alpha 1-proteinase inhibitor**	J0257
Granix**	tbo-filgrastim**	J1447
Haegarda	c1 esterase inhibitor (subcutaneous_	J0599
Herceptin**	trastuzumab <sup>**</sup>	J9355
Herceptin Hylecta <sup>‡,**</sup>	trastuzumab and hyaluronidase- oysk <sup>‡,**</sup>	J9356
Hercessi IV	trastuzumab-strf **	Q5146
Herzuma**	trastuzumab-pkrb <sup>**</sup>	Q5113
Hizentra	immune globulin	J1559
Hyalgan <sup>‡,**</sup>	sodium hyaluronate <sup>‡,**</sup>	J7321
Hymovis <sup>**</sup>	sodium hyaluronate**	J7322
Hyqvia**	immune globulin**	J1575
iDose TR 75mcg intracameral implant	travoprost intracameral implant	J7355

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Ilaris	canakinumab	J0638
Ilumya**	tildrakizumab-asmn <sup>**</sup>	J3245
Iluvien	fluocinolone acetonide	J7313
Imaavy <sup>‡,**</sup>	nipocalimab-aahu <sup>‡,**</sup>	C9305, J3490, J3590
Imdelltra	tarlatamab-dlle	J9026
Imfinzi <sup>**</sup>	durvalumab**	J9173
Imjudo **	tremelimumab-actl **	J9347
Imlygic	talimogene laherparepvec	J9325
Imuldosa IV	ustekinumab-srlf *,†,**	Q5098
Inflectra	infliximab-dyyb	Q5103
Infliximab	infliximab	J1745
Injectafer**	ferric carboxymaltose**	J1439
Inlexzo	gemcitabine intravesical system	C9399, J3490, J9999
Istodax	romidespin	J9319
Ixempra	ixabepilone	J9207
Izervay	avacincaptad pegol intravitreal solution	J2782
Jelmyto <sup>‡</sup>	mitomycin <sup>‡</sup>	J9281
Jemperli	dostarlimab-gxly	J9272
Jevtana	cabazitaxel	J9043
*,t,非*** Jobevne	bevacizumab-nwgd *,†,‡,**	C9399, J3490, J3590, J9999

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Jubbonti <sup>‡</sup>	denosumab-bbdz <sup>‡</sup>	Q5136
Kadcyla	ado-trastuzumab emtansine	J9354
Kalbitor**	ecallantide <sup>**</sup>	J1290
Kanjinti	trastuzumab-anns	Q5117
Kanuma	sebelipase alfa	J2840
Kebilidi <sup>‡,††</sup>	eladocagene exuparvovec-tneq	C9399, J3490, J3590
Keytruda <sup>**</sup>	pembrolizumab <sup>**</sup>	J9271
Khapzory	levoleucovorin	J0642
Kimmtrak	tebentafusp-tebn	J9274
Kisunla	donanemab-azbt	J0175
Korsuva ‡	difelikefalin <sup>‡</sup>	J0879
Krystexxa	pegloticase	J2507
Kymriah <sup>††</sup>	tisagenlecleucel <sup>††</sup>	Q2042
Kyprolis	carfilzomib	J9047
t,*,‡ Kyxata	carboplatin <sup>†, *, ‡</sup>	C9399, J3490, 9999
Lamzede	velmanase alfa-tycv	J0217
‡,†† Lantidra	donislecel-jujn <sup>‡,††</sup>	C9399, J3490, J3590
lanreotide <sup>‡</sup>	lanreotide <sup>‡</sup>	J1930
lanreotide (Cipla)	lanreotide	J1932
Lemtrada **	alemtuzumab **	J0202

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Lenmeldy <sup>††</sup>	atidarsagene autotemcel <sup>††</sup>	J3391
Leqembi	lecanemab-irmb	J0174
Leqembi Iqlik <sup>†, *</sup>	lecanemab-irmb <sup>†, *</sup>	C9399, J3490, J3590
Leqvio	inclisiran	J1306
Leukine	sargramostim	J2820
Levoleucovorin <sup>‡</sup>	levoleucovorin calcium <sup>‡</sup>	J0641
Libtayo	cemiplimab-rwlc	J9119
Loqtorzi	toripalimab-tpzi	J3263
Lucentis**	ranibizumab <sup>**</sup>	J2778
Lumizyme	alglucosidase alfa	J0221
Lunsumio	mosunetuzumab-axgb	J9350
Lutathera**	lutetium Lu 177 dotatate**	A9513
Luxturna	voretigene neparvovec-rzyl	J3398
Lyfgenia H	lovotibeglogene autotemcel	J3394
Lynozyfic	linvoseltamab-gcpt	C9399, J3490, J3590, J9999
Margenza	margetuximab-cmkb	J9353
Mepsevii	vestronidase alfa-vjbk	J3397
Mircera	methoxy polyethylene glycol-epoetin beta	J0888
Monjuvi <sup>‡</sup>	tafasitamab-cxix <sup>‡</sup>	J9349
Monoferric**	ferric derisomaltose**	J1437

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Mozobil <sup>‡</sup>	plerixafor <sup>‡</sup>	J2562
Mvasi	bevacizumab-awwb	Q5107
Mylotarg	gemtuzumab ozogamicin	J9203
Myobloc	rimabotulinumtoxinB	J0587
Naglazyme	galsulfase	J1458
Neulasta <sup>‡</sup>	pegfilgrastim <sup>‡</sup>	J2506
Neulasta Onpro <sup>‡</sup>	pegfilgrastim <sup>‡</sup>	J2506
Neupogen**	filgrastim**	J1442
Nexviazyme	avalglucosidase alfa-ngpt	J0219
Ngenla <sup>‡</sup>	somatrogon-ghla <sup>‡</sup>	C9399, J3490, J3590
Niktimvo IV	axatilimab-csfr	J9038
Nivestym **	filgrastim-aafi **	Q5110
Nplate	romiplostim	J2802
Nucala	mepolizumab	J2182
Nulibry	fosdenopterin	J1809
Nypozi **	filgrastim-txid **	Q5148
Nyvepria**	pegfilgrastim-apgf <sup>**</sup>	Q5122
Ocrevus	ocrelizumab	J2350
Ocrevus Zunovo	ocrelizumab and hyaluronidase-acsq	J2351
Octagam	immune globulin	J1568
Ogivri**	trastuzumab-dkst**	Q5114

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Omisirge <sup>‡,††</sup>	omidubicel-onlv <sup>‡,††</sup>	C9399, J3490, J3590
Omvoh IV	mirikizumab-mrkz	J2267
Onapgo SQ cartridge ‡	apomorphine hydrochloride ‡	C9399, J3490
Oncaspar	pegaspargase	J9266
Onivyde	irinotecan liposome injection	J9205
Onpattro	patisiran	J0222
Ontruzant**	trastuzumab-dttb <sup>**</sup>	Q5112
Opdivo**	nivolumab <sup>**</sup>	J9299
Opdivo Qvantig	nivolumab and hyaluronidase-nvhy	J9289
Opdualag intravenous vial	nivolumab and relatlimab-rmbw injection	J9298
Orencia IV**	abatacept**	J0129
Osenvelt t, ‡, *,**	denosumab-bmwo <sup>†, ‡, *,**</sup>	Q5157
Otulfi IV	ustekinumab-aauz	Q9999
Oxlumo	lumasiran	J0224
Ozurdex	dexamethasone intravitreal implant	J7312
paclitaxel protein-bound **	paclitaxel protein-bound**	J9264
Padcev <sup>‡</sup>	enfortumab vedotin-ejfv <sup>‡</sup>	J9177
Palynziq <sup>‡</sup>	pegvaliase-pqpz <sup>‡</sup>	C9399, J3490, J3590
Panhematin <sup>*</sup>	hemin <sup>*</sup>	J1640
Panzyga **	immune globulin **	J1576

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Papzimeos t,*,‡	zopapogene imadenovec-drba <sup>†, *, ‡</sup>	C9399, J3490, J3590
Pavblu **	aflibercept-ayyh **	Q5147
Pedmark IV solution	sodium thiosulfate	J0208
pemetrexed	pemetrexed	J9305
pemetrexed (Accord)	pemetrexed	J9296
pemetrexed (Bluepoint)	pemetrexed	J9322
pemetrexed (Sandoz)	pemetrexed	J9297
pemetrexed (Teva)	pemetrexed	J9314
pemetrexed disodium (Hospira)	pemetrexed disodium	J9294
pemetrexed ditromethamine	pemetrexed ditromethamine	J9323
Pemfexy	pemetrexed injection	J9304
Pemrydi RTU	pemetrexed	J9324
Perjeta	pertuzumab	J9306
Phesgo <sup>‡</sup>	pertuzumab, trastuzumab, and hyaluronidase-zzxf <sup>‡</sup>	J9316
Piasky **	crovalimab-akkz **	J1307
plerixafor <sup>‡</sup>	plerixafor <sup>‡</sup>	J2562
Pluvicto	lutetium lu 177 vipivotide tetraxetan	A9607
Polivy	polatuzumab vedotin-piiq	J9309
Pombiliti	cipaglucosidase alfa-atga	J1203
Portrazza	necitumumab	J9295

### Humana,

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Poteligeo	mogamulizumab-kpkc	J9204
pralatrexate IV <sup>‡</sup>	pralatrexate <sup>‡</sup>	J9307
Prevymis IV <sup>‡</sup>	letermovir <sup>‡</sup>	C9399, J3490
Prialt	ziconotide	J2278
Privigen	immune globulin	J1459
Procrit <sup>‡</sup>	epoetin alfa <sup>‡</sup>	J0885
Prolastin-C <sup>‡,**</sup>	alpha 1-proteinase inhibitor <sup>‡,**</sup>	J0256
Prolia	denosumab	J0897
Provenge	sipuleucel-T	Q2043
Pyzchiva IV	ustekinumab-ttwe*	Q9997
Qalsody	tofersen	J1304
Qutenza	capsaicin/skin cleanser	J7336
Radicava	edaravone	J1301
Reblozyl <sup>**</sup>	luspatercept-aamt <sup>‡,**</sup>	J0896
Releuko**	filgrastim-ayow injection**	Q5125
Remicade	infliximab	J1745
Remodulin <sup>‡</sup>	treprostinil (injection) <sup>‡</sup>	J3285
Renflexis <sup>**</sup>	infliximab-abda <sup>**</sup>	Q5104
Retacrit	epoetin alfa-epbx	Q5106
Rethymic <sup>‡,††</sup>	allogeneic processed thymus tissue- agdc <sup>‡,††</sup>	C9399, J3490, J3590

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Riabni**	rituximab-arrx**	Q5123
Rituxan IV**	rituximab IV <sup>**</sup>	J9312
Rituxan Hycela**	rituximab/hyaluronidase human**	J9311
Rolvedon	eflapegrastim-xnst	J1449
romidepsin	romidepsin	J9318
Ruconest**	c1 esterase inhibitor**	J0596
Ruxience**	rituximab-pvvr**	Q5119
Rybrevant IV	amivantamab-vmjw	J9061
Rylaze	asparaginase erwinia chrysanthemi (recombinant)-rywn	J9021
Ryoncil <sup>††</sup>	remestemcel-L-rknd <sup>††</sup>	J3402
Ryplazim	plasminogen, human-tvmh	J2998
Rystiggo	rozanolixizumab-noli*	J9333
Rytelo IV	imetelstat	J0870
Ryzneuta **	efbemalenograstim alfa-vuxw **	C9399, J3490, J3590, J9999
Sajazir <sup>‡</sup>	icatibant <sup>‡</sup>	J1744
Sandostatin LAR	octreotide	J2353
Saphnelo intravenous solution	anifrolumab-fnia	J0491
Sarclisa <sup>‡</sup>	isatuximab-irfc <sup>‡</sup>	J9227
Scenesse <sup>‡</sup>	afamelanotide <sup>‡</sup>	J7352
Selarsdi IV <sup>‡,**</sup>	ustekinumab-aekn <sup>‡,**</sup>	Q9998

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Signifor LAR	pasireotide	J2502
Simponi ARIA	golimumab	J1602
Sinuva	mometasone furoate	J7402
Skyrizi IV	risankizumab-rzaa	J2327
Skysona <sup>‡,††</sup>	elivaldogene autotemcel <sup>‡,††</sup>	C9399, J3490, J3590
sodium thiosulfate (Hope)	sodium thiosulfate	J0209
Soliris **	eculizumab **	J1299
Somatuline Depot <sup>‡</sup>	lanreotide <sup>‡</sup>	J1930
Spevigo IV	spesolimab-sbzo	J1747
Spinraza	nusinersen	J2326
Stelara (IV) <sup>‡</sup>	ustekinumab <sup>‡</sup>	J3358
Steqeyma IV t, *,**	ustekinumab-stba t,*,***	Q5099
Stimufend **	pegfilgrastim-fpgk	Q5127
Stoboclo t, t, *, *, **	denosumab-bmwo t, ‡, *, ***	Q5157
Sustol	granisetron	J1627
Susvimo **	ranibizumab **	J2779
Syfovre	pegcetacopian	J2781
SynoJoynt **	1% sodium hyaluronate **	J7331
Synribo	omacetaxine mepesuccinate	J9262
Synvisc <sup>‡,**</sup>	hylan G-F 20 <sup>‡,**</sup>	J7325

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Takhzyro**	lanadelumab-flyo <sup>**</sup>	J0593
Talvey	talquetamab-tgvs	J3055
Tecartus <sup>††</sup>	brexucabtagene autoeucel <sup>††</sup>	Q2053
Tecelra <sup>††</sup>	afamitresgene autoleucel <sup>††</sup>	Q2057
Tecentriq**	atezolizumab**	J9022
Tecentric Hybreza SQ**	atezolizumab and hyaluronidase- tąjs**	J9024
Tecvayli	teclistamab-cqyv	J9380
Tepezza <sup>‡</sup>	teprotumumab-trbw <sup>‡</sup>	J3241
Tevimbra	tislelizumab-jsgr	J9329
Tezspire	tezepelumab-ekko	J2356
Tezspire subcutaneous pen injector	tezepelumab-ekko	J2356
Tivdak **	tisotumab vedotin-tftv **	J9273
Thrombate III	antithrombin III (human)	J7197
Tofidence IV **	tocilizumab-bavi **	Q5133
Trazimera	trastuzumab-qyyp	Q5116
Treanda	bendamustine hydrochloride	J9033
Tremfya IV <sup>‡</sup>	guselkumab <sup>‡</sup>	J1628
Triluron**	sodium hyaluronate <sup>**</sup>	J7332
Trisenox	arsenic trioxide	J9017
TriVisc**	sodium hyaluronate**	J7329
Trodelvy <sup>‡</sup>	sacituzumab govitecan-hziy <sup>‡</sup>	J9317

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Truxima**	rituximab-abbs**	Q5115
Tyenne IV **	tocilizumab-aazg **	Q5135
Tysabri**	natalizumab**	J2323
Tyvaso	treprostinil (inhaled)	J7686
Tzield	teplizumab-mzwv	J9381
Udenyca ‡	pegfilgrastim-cbqv <sup>‡</sup>	Q5111
Udenyca autoinjector ‡	pegfilgrastim-cbqv ‡	Q5111
Udenyca Onbody <sup>‡</sup>	pegfilgrastim-cbqv ‡	Q5111
Ultomiris	ravulizumab-cwvz	J1303
Unituxin <sup>‡</sup>	dinutuximab <sup>‡</sup>	C9399, J3490
Unloxcyt <sup>t,*</sup>	cosibelimab-ipdl t,*	J9275
Uplizna <sup>‡</sup>	inebilizumab-cdon <sup>‡</sup>	J1823
Ustekinumab IV <sup>‡,**</sup>	ustekinumab <sup>‡,**</sup>	J3358
Vabysmo**	faricimab-svoa injection**	J2777
Valstar	valrubicin	J9357
Vectibix	panitumumab	J9303
Vegzelma **	bevacizumab-adcd **	Q5129
Velcade <sup>‡</sup>	bortezomib <sup>‡</sup>	J9041
Veopoz	pozelimab-bbfg	J9376
Viltepso	viltolarsen	J1427

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Vimizim	elosulfase alfa	J1322
Visco-3 <sup>‡,**</sup>	sodium hyaluronate <sup>‡,**</sup>	J7321
Vivimusta	bendamustine hydrochloride	J9056
Vpriv**	velaglucerase alfa <sup>**</sup>	J3385
Vyepti <sup>‡</sup>	eptinezumab-jjmr <sup>‡</sup>	J3032
Vyjuvek	beremagene geperpavec-svdt	J3401
Vyloy	zolbetuximab-clzb	J1326
Vyondys 53	golodirsen	J1429
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase- qvfc	J9334
Vyvgart intravenous solution	efgartigimod alfa-fcab	J9332
Vyxeos	daunorubicin/cytarabine	J9153
Wainua <sup>‡</sup>	eplontersen injection <sup>‡</sup>	C9399, J3490
Wezlana IV *, †, **	ustekinumab-auub <sup>*, †, **</sup>	Q5138
Wyost **	denosumab-bbdz**	Q5136
Xembify	immune globulin	J1558
Xenpozyme	olipudase alfa-rpcp	J0218
Xeomin	incobotulinumtoxin A	J0588
Xgeva <sup>‡,**</sup>	denosumab <sup>‡,**</sup>	J0897
Xipere	triamcinolone acetonide	J3299
Xofigo	radium Ra 223 dichloride	A9606
Xolair	omalizumab	J2357

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Yervoy**	ipilimumab**	J9228
Yescarta <sup>††</sup>	axicabtagene ciloleucel <sup>††</sup>	Q2041
Yesintek IV **	ustekinumab-kfce **	Q5100
Yimmugo <sup>†, ‡, *,**</sup>	immune globulin intravenous, human-dira	C9399, J3490, J3590
Yondelis	trabectedin	J9352
Zaltrap	ziv-aflibercept	J9400
Zarxio	filgrastim-sndz	Q5101
Zemaira <sup>‡</sup>	alpha 1-proteinase inhibitor <sup>‡</sup>	J0256
Zepzelca <sup>‡</sup>	lurbinectedin <sup>‡</sup>	J9223
Zevalin	ibritumomab tiuxetan	A9543
Zevaskyn <sup>t, ‡, *,††</sup>	prademagene zamikeracel t, ‡, *,††	C9399, J3490, J3590
Ziextenzo**	pegfilgrastim-bmez**	Q5120
Ziihera	zanidatamab-hrii	J9276
Zilretta **	triamcinolone acetonide **	J3304
Zirabev	bevacizumab-bvzr	Q5118
Zoladex	goserelin acetate	J9202
Zolgensma <sup>‡</sup>	onasemnogene abeparvovec-xioi‡	J3399
Zusduri <sup>†, ‡, *</sup>	mitomycin t, ‡, *	C9399, J3490, J9999
Zynlonta	loncastuximab tesirine-lpyl	J9359
Zynteglo <sup>††</sup>	betibeglogene autotemcel <sup>††</sup>	J3393

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Zynyz	retifanlimab-dlwr	J9345
Blood-clotting Factors		
Advate <sup>‡</sup>	antihemophilic factor (recombinant)‡	J7192
Adynovate	antihemophilic factor (recombinant), PEGylated	J7207
Afstyla	antihemophilic factor (recombinant) single chain	J7210
Alhemo	concizumab-mtci	J7173
Alphanate	antihemophilic factor/von Willebrand factor complex (human)	J7186
AlphaNine SD	coagulation factor IX (human)	J7193
Alprolix	coagulation factor IX (recombinant)	J7201
Altuviiio	efanesoctocog alfa	J7214
BeneFix <sup>‡</sup>	coagulation factor IX (recombinant) <sup>‡</sup>	J7195
Beqvez	fidanacogene elaparvovec-dzkt	J1414
Coagadex	coagulation factor X (human)	J7175
Corifact	factor XIII concentrate (human)	J7180
Eloctate	antihemophilic factor (recombinant), Fc fusion protein	J7205
Esperoct	antihemophilic factor (recombinant), glycopegylated-exei	J7204
Feiba NF	anti-inhibitor coagulant complex	J7198
Hemgenix	etranacogene dezaparvovec-drlb	J1411
Hemlibra**	emicizumab-kxwh <sup>**</sup>	J7170

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

Hemofil M <sup>‡</sup>	antihemophilic factor (human) <sup>‡</sup>	J7190
Humate-P	antihemophilic factor/von Willebrand factor complex (human)	J7187
Hympavzi**	marstacimab-hncq**	J7172
Idelvion	coagulation factor IX (recombinant)‡	J7202
Ixinity <sup>‡</sup>	coagulation factor IX (recombinant)‡	J7213
Jivi <sup>‡</sup>	antihemophilic factor (recombinant), PEGylated-aucl <sup>‡</sup>	J7208
Koate-DVI <sup>‡</sup>	antihemophilic factor (human) ‡	J7190
Kogenate FS <sup>‡</sup>	antihemophilic factor (recombinant) ‡	J7192
Kovaltry	antihemophilic factor (recombinant)	J7211
NovoEight	turoctocog alfa	J7182
NovoSeven RT	coagulation factor VIIa (recombinant)	J7189
Nuwiq	simoctocog alfa	J7209
Obizur	antihemophilic factor (recombinant), porcine sequence	J7188
Profilnine <sup>‡</sup>	factor IX complex <sup>‡</sup>	J7194
Qfitlia **	fitusiran	J7174
Rebinyn	coagulation factor IX (recombinant), GlycoPEGylated	J7203
Recombinate <sup>‡</sup>	antihemophilic factor (recombinant) ‡	J7192
Rixubis	coagulation factor IX (recombinant)	J7200
Roctavian	valoctocogene roxaparvovec-rvox	J1412

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- †† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.

SevenFact intravenous solution <sup>‡</sup>	coagulation factor VIIa (recombinant)-jncw <sup>‡</sup>	J7212
Tretten	coagulation factor XIII A-subunit (recombinant)	J7181
Vonvendi	von Willebrand factor (recombinant)	J7179
Wilate	von Willebrand factor/coagulation factor VIII complex (human)	J7183
Xyntha	antihemophilic factor (recombinant)	J7185
Xyntha Solofuse	antihemophilic factor (recombinant)	J7185

- \* New preauthorization requirement
- † New-to-market drug addition
- ‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
- \*\* Step therapy required through a Humana-preferred drug as part of preauthorization.
- **††** Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300; by phone at 866-421-5663, Monday Friday, 7 a.m. 7 p.m., Central time; or by email to transplant@humana.com.